Cytokinetics Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/15/2026)
| Balance Sheet | Total Assets | 1,424,540,000.00 | ROE | -46.30 % |
| Balance Sheet | Total Equity | -659,625,000.00 | ROA | -55.10 % |
| Cashflow | Capital Expenditures | -24,807,000.00 | P/FCF | -14.24 |
| Cashflow | Free Cash Flow | -534,816,000.00 | – | – |
| Cashflow | Operating Cash Flow | -510,009,000.00 | P/CF | -14.94 |
| Income | Earnings per Share (diluted) | -6.54 | Div. Yield | – |
| Income | Net Income | -784,955,000.00 | P/E | -9.70 |
| Income | Shares Outstanding | 120,103,000.00 | P/B | -11.55 |
| Income | Total Revenue | 88,039,000.00 | P/S | 86.53 |
Ratios calculated on: 10/14/2026
Company Description
Cytokinetics, Incorporated (Cytokinetics) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The Company´s research and development programs relating to the biology of muscle function are directed to small molecule modulators of the contractility of cardiac, skeletal and smooth muscle. The cardiac muscle contractility program is focused on cardiac sarcomere, the basic unit of muscle contraction in the heart. Its lead drug candidate CK-2017357 is subject of a Phase IIa clinical trials program. CK-2017357 is useful in treating diseases or medical conditions associated with skeletal muscle weakness or wasting. In March 2010, CK-2017357 received an orphan drug designation from the FDA for the treatment of amyotrophic lateral sclerosis.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.cytokinetics.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more